Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of ...

Merck Announces KEYTRUDA Plus WELIREG Met Primary Endpoint of DFS in Certain Patients With Clear Cell Renal Cell Carcinoma ...

During a live event, Randy F. Sweis, MD, and participants discussed treating non–clear cell renal cell carcinoma based on ...

Xencor's clear cell renal cell carcinoma treatment demonstrated evidence of anti-tumor activity in a phase 1 trial.

Sweis, MD, and participants discussed their impressions of combination trials in non–clear cell renal cell carcinoma. Non-clear cell renal cell carcinoma (nccRCC) is a less common disease state than ...

A study from the University of Michigan Health Rogel Cancer Center and Department of Pathology shows that further testing in ...

A substudy of the phase 1/2 KEYMAKER-U03 trial tested novel pembrolizumab-based triplet regimens for first-line treatment of advanced clear cell renal cell carcinoma (ccRCC).

Detailed price information for Bristol-Myers Squibb Company (BMY-N) from The Globe and Mail including charting and trades.

Results of CheckMate 67T, a phase 3 noninferiority study comparing subcutaneous and intravenous nivolumab formulations in RCC, were presented at JADPRO 2025.

Researchers at The University of Texas MD Anderson Cancer Center, in collaboration with BostonGene, conducted the largest and ...

Investigators presented initial results from a phase 3 trial of adjuvant durvalumab plus tremelimumab for resected primary renal cell carcinoma (RCC).